ANDA Submissions Continue Yo-Yo Pattern, Unlike Approvals
Executive Summary
After spike in March, generic drug application submissions drop 62% in April, while approval volume remains at monthly average.
You may also be interested in...
Generic Drug Puzzle: Why Did ANDA Submissions Spike Again?
Jump in March may have been "happenstance," but also could be concerning as US ANDA submissions reach near record pace.
ANDA Stress Test: End-Of-Year Submission Bolus Pressures US FDA Review System
As more generic applications arrive, Office of Generic Drugs staff may have a tougher time reaching review goals.
Another ANDA Submission Surge Begins
US FDA receives more than 100 ANDAs during the first month of GDUFA year five, suggesting sponsors want the new 10-month review goal and cheaper user fee.